Quince Therapeutics, Inc. Common Stock (QNCX)

Health Care·equity
$31.73
+8.07% today
Extended hours $31.88
Prices delayed about 15 minutes · cached page, can be an hour old or more
Market Census Score
49/ 100
Score level
Average
5 of 6 checks had data

How it compares with the broader market is one of its highest-scoring factors; business numbers score is on the low side, price trend score is on the low side.

QNCX scores higher than 66% of the 1,101 tickers we compare it with (Health Care).

As of 9 October 2026, Quince Therapeutics, Inc. Common Stock (QNCX) scores 49 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.

Updated · scores usually change about once a day

Insider trades: no reading heldTrendStrengthFinancialsInsidersInsider trades: no reading heldMarketMomentum49/ 100

Key statistics

Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.

Relative volume
5.21× 30-day average
52-week range
15.10 – 909.98
Market cap
$29.98M
Earnings date
10 Nov 2026
Volume
138,729
Avg. volume (30d)
26,610
Open
30.50
Previous close
29.36
Day's range (regular session)
29.84 – 37.00

The last trade can be an extended-hours trade, so it can sit outside the regular-session range.

Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.

Beta
—
P/E (TTM)
—
EPS (TTM)
—

Score breakdown · six named factors

Price trend
35
Strength vs the market
100
Company finances
0
Insider trades
—
Market mood
50
Recent momentum
59

Each bar is one part of the score, from 0 to 100. Read what the score means.

What the score says about QNCX right now

Quince Therapeutics, Inc. Common Stock (QNCX) currently scores 49/100 on the Market Census six-factor composite, at the Average score level. QNCX is +8.07% on the day and +4.76% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in QNCX's data roughly balance out right now. QNCX's strongest factor is strength vs the market at 100/100 — a very strong read on how QNCX has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.

Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.

See QNCX in the scanner

This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).

Recent QNCX news

Latest headlines that name Quince Therapeutics, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).

We hide 3 more that told readers to buy or sell, or gave a price target.

Saved snapshot; the news and prices on this page can be an hour old or more.

Similar setups in Health Care right now

Six health care tickers whose composite scores are closest to QNCX’s 49, all within 1 point.

Sorted by closeness to QNCX’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →

Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.

QNCX Stock Score & 6-Factor Analysis · Market Census